Biotechnology - Biotechnology, Cardio-vascular

Filter

Popular Filters

1 to 25 of 95 results

Regado Biosciences announces FDA’s clinical hold of Ph III trial

Regado Biosciences announces FDA’s clinical hold of Ph III trial

10-07-2014

The US Food and Drug Administration (FDA) has informed US-based cardiovascular specialist Regado Biosciences…

Acute coronary syndromeBiotechnologybivalirudinCardio-vascularMedicineRegadoRegulationUSA

AADi in-licenses Celgene’s ABI-009

20-05-2014

US clinical-stage biopharma company AADi says it has in-licensed ABI-009 from biotech firm Celgene. Financial…

AADiABI-009BiotechnologyCardio-vascularCelgeneOncologyRespiratory and Pulmonary

Evolocumab combined with statin results in further reduction of cholesterol levels

Evolocumab combined with statin results in further reduction of cholesterol levels

14-05-2014

Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition…

AmgenBiotechnologyCardio-vascularevolocumabResearch

Encouraging results with Gilead’s combo ranolazine and dronedarone in AFB

Encouraging results with Gilead’s combo ranolazine and dronedarone in AFB

12-05-2014

US antiviral specialist Gilead Sciences has released positive results from HARMONY, a randomized, double-blind,…

BiotechnologyCardio-vasculardronedaroneGilead SciencesRanolazineResearch

Heart Metabolics raises $20 million for Phase III heart disease drug trial

17-04-2014

Irish biotech company Heart Metabolics has completed a $20 million round of financing to support its…

BiotechnologyCardio-metabolic diseasesCardio-vascularDrug discoveryFinancialHeart diseaseHeart Metabolics LimitedIrelandPeter Milner

Amarin and Kowa Pharma to co-promote Vascepa in USA

01-04-2014

US biotech firm Amarin Corp and Kowa Pharmaceuticals America, owned by Japan’s Kowa, have reached an…

AmarinBiotechnologyCardio-vascularKowa PharmaceuticalsMarkets & MarketingNorth AmericaUSAVascepa

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

31-03-2014

USA-based Amgen announced data at the American College of Cardiology 63rd Annual Scientific Session this…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

More positive Ph III data for Amgen’s evolocumab

More positive Ph III data for Amgen’s evolocumab

17-03-2014

Leading independent biotech firm Amgen has released more positive clinical trial data with its cholesterol…

AmgenBiotechnologyCardio-vascularevolocumabRare diseasesResearch

Amarin files suit against AstraZeneca over Epanova

Amarin files suit against AstraZeneca over Epanova

05-03-2014

US biotech firm Amarin revealed in a Stock Exchange Commission submission that it has filed a complaint…

AmarinAstraZenecaBiotechnologyCardio-vascularEpanovaLegalNorth AmericaOmthera PharmaceuticalsPatentsUSAVascepa

Amarin calls on FDA to extend Vascepa exclusivity by five years

28-02-2014

US biotech firm Amarin has filed with a federal court requesting it to order the US Food and Drug Administration…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLegalLovazaNorth AmericaUSAVascepa

Actelion’s Opsumit approved by SwissMedic for PAH patients

Actelion’s Opsumit approved by SwissMedic for PAH patients

14-02-2014

Swiss biotech firm Actelion announced today that SwissMedic has approved Opsumit (macitentan) for pulmonary…

ActelionBiotechnologyCardio-vascularNorthern EuropeOpsumitRegulation

Actelion gains approval in Australia for Opsumit in PAH

Actelion gains approval in Australia for Opsumit in PAH

07-02-2014

Swiss biotech firm Actelion (SIX: ATLN) has received approval of Opsumit (macitentan) for the treatment…

ActelionAustraliaBiotechnologyCardio-vascularOpsumitRegulation

Amgen announces top-line results from Phase III trial of evolocumab

Amgen announces top-line results from Phase III trial of evolocumab

29-01-2014

USA-based Amgen announced that the Phase III LAPLACE-2 trial evaluating evolocumab (AMG 145) in combination…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

24-01-2014

USA-based Amgen yesterday revealed positive results from the Phase III GAUSS-2 (Goal Achievement After…

AmgenBiotechnologyCardio-vascularevolocumabResearchZetia

New nanoparticle therapy reduces damage after heart attack

22-01-2014

Privately-held US biopharma company Cour Pharmaceutical Development reports the publication of new data…

BiotechnologyCardio-vascularCour Pharmaceutical DevelopmentResearch

Surprise FDA advisory panel backing for Chelsea’s Northera

Surprise FDA advisory panel backing for Chelsea’s Northera

15-01-2014

A US Food and Drug Administration advisory panel has voted 16-one to recommend approval of US biotech…

BiotechnologyCardio-vascularChelsea TherapeuticsNorth AmericaNortheraRegulationUSA

Nanomedicines market to reach $177.6 billion globally in 2019

08-01-2014

The global market for nanomedicine was valued at $78.54 billion in 2012 and is expected to reach a value…

BiotechnologyCardio-vascularGlobalMarkets & MarketingOncology

Capricor Therapeutics and Janssen collaborate on cell therapy program

Capricor Therapeutics and Janssen collaborate on cell therapy program

07-01-2014

California, USA-based Capricor Therapeutics says it has executed a collaboration agreement and exclusive…

BiotechnologyCAP-1002Capricor TherapeuticsCardio-vascularJanssen BiotechJohnson & JohnsonLicensing

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

18-12-2013

USA-based biotech company Amgen (Nasdaq: AMGN) has revealed positive top-line Phase III results for its…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

20-11-2013

USA-based biotech firm Amgen (Nasdaq: AMGN) has said its investigational PCSK9 inhibitor evolocumab helped…

AmgenBiotechnologyCardio-vascularevolocumabNorth AmericaResearchUSA

Actelion presents positive trial data for Opsumit in PAH

Actelion presents positive trial data for Opsumit in PAH

29-10-2013

Swiss biotech firm Actelion will present data on the efficacy of Opsumit from the SERAPHIN study at CHEST…

ActelionBiotechnologyCardio-vascularNorth AmericaOpsumitResearch

US FDA gives nod to Actelion’s PAH drug Opsumit

US FDA gives nod to Actelion’s PAH drug Opsumit

21-10-2013

The US Food and Drug Administration has approved Actelion's pulmonary arterial hypertension drug Opsumit…

ActelionBiotechnologyCardio-vascularNorth AmericaOpsumitRegulation

Actelion’s PAH drugs boost 4% rise in sales

Actelion’s PAH drugs boost 4% rise in sales

17-10-2013

Actelion has announced its financial results for the first nine months of 2013 revealing product sales…

ActelionBiotechnologyCardio-vascularCeptaris TherapeuticsEuropeFinancialTracleerVeletriVentavisZavesca

1 to 25 of 95 results

Back to top